JPRN-UMIN000002014已完成3 期
Phase III study of gefitinib versus erlotinib in patients with previously treated lung adeno carcinoma - gefitinib versus erlotinib in patients with previously treated lung adeno carcinoma (WJOG5108)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 560
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of obvious and widely distributed interstitial pneumonia or pulmonary fibrosis detected by chest CT 2)History of drug induced interstitial pneumonia 3)History of severe drug allergy 4)History of radiation therapy for mediastinum or lung within 14 days at the time of entry. (Radiation therapy for other parts is not adapted for this exclusion cliteria.) 5)History of poorly controlled pleural effusion, pericardial effusion or ascites necessitating drainage 6)History of active infection 7)History of persistent watery diarrhea 8)History of ileus 9)Patients who are not take in drug orally 10)History of symptomatic brain metastases. 11)History of active double cancer 12)History of poorly controlled cardiac diseases. 13)History of active psychological disease. 14) History of pregnancy or lactation 15) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
已完成
不适用
A phase II study of erlotinib for gefitinib-resistant non-small cell lung cancer without T790M mutation analyzed in the circulating tumor cellon-small cell lung cancerJPRN-UMIN000004046orth-East Japan Study Group20
已完成
不适用
Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)on-small cell lung cancerJPRN-UMIN000006340orth-East Japan Study Group345
已完成
3 期
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)advanced non-squamous non-small cell lung cancer harboring EGFR mutaitonJPRN-UMIN000020242Japan Clinical Oncology Group (JCOG)500
撤回
2 期
A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitorsadvanced stage non-small cell lung cancermetastatic non-small cell lung cancer1003866610029107NL-OMON37908Vrije Universiteit Medisch Centrum48
进行中（未招募）
不适用
Treatment with gefitinib and fulvestrant in patients with non-small cell lungcancerPatients with pathologically documented NSCLC with an EGFR mutation, who failed previous treatment with reversible EGFR TKI’s (gefitinib or erlotinib).EUCTR2012-000345-12-NLVU Medical Center